Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema

Vol.22 No.6

Case Report

Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema

Authors

Noriko Umegaki¹ , Masahiro Kira¹ , Takahiko Horiuchi² , Saori Itoi¹ , Mamori Tani¹ , Akinori Yokomi¹ , Atsushi Tanemura¹ , Hisaaki Miyahara³ , Michiyo Hatanaka⁴ , Hajime Kitamura⁴ , Etsuko Kitano⁴ , Ichiro Katayama¹

Department of Dermatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
NHO Kyushu Medical Center, Fukuoka, Japan
Department of Medical Technology, Faculty of Health Sciences, Kobe Tokiwa University, Kobe, Japan

Received:

9 November 2011

Accepted:

19 January 2012

Published online:

5 February 2012

Full Text

PDF　(member's only)

Abstract

Hereditary angioedema (HAE) is a life-threatening disorder caused by deficiency or dysfunction of the C1 inhibitor protein. Patients with HAE are restricted in various medical treatments, which can induce an HAE attack. We herein report the first case of psoriatic arthritis (PSA) with type 1 HAE successfully treated with 25 mg of etanercept without HAE attack. Etanercept may represent a useful choice for treating patients with HAE accompanied by intractable PSA and rheumatoid arthritis (RA).

Key words

Psoriatic arthritis - Hereditary angioedema - Biological agent - Etanercept